99MTc-PSMA – radionuclide imaging of prostate cancer: an innovative diagnostic direction in nuclear medicine-Reference-Cited by-同舟云学术

99MTc-PSMA – radionuclide imaging of prostate cancer: an innovative diagnostic direction in nuclear medicine

Published:2020 Issue:3 Volume: Page:26-38
ISSN:2707-0700
Container-title:Radiation Diagnostics, Radiation Therapy
language:
Short-container-title:RDRT

Author:

Korol P.¹^ORCID,Tkachenko M.²,Voloshin A.³

Affiliation:

1. Kiev city clinical hospital # 12;.A. Bohomolets National Medical University

2. O. Bogomolets National Medical University, Kyiv, Ukraine

3. Kiev city clinical hospital # 12

Abstract

The literature review considers the prospects for the use of SPECT and PET imaging with 99mTc-PSMA as an innovative method for diagnosing prostate cancer. SPECT studies with 111In-PSMA-I have further expanded the scope of modern therapeutic concepts aimed at PSMA. However, the inherent limitations associated with 111In preclude the wider clinical use of 111In-PSMA-I and T, in addition to studies confirming the concept, in small cohorts of patients. The total body clearance of 99mTc-PSMA-I and S is relatively slow, which results in a relatively late clearance in the abdominal region. However, the accumulation of the radiopharmaceutical in previously identified areas of tumor lesions steadily grows over time due to the prolonged presence of an intact indicator in the blood and its internalization into tumor cells with high PSMA expression. In a delayed period, an excellent lesion-background ratio is obtained due to the synergistic effect of stable uptake of 99mTc-PSMA-I and S in tumor tissue and the continuation of the clearance of background activity. Several alternative therapeutic approaches have been implemented to provide a universal molecular platform for labeling with diagnostic (123I / 124I, 68Ga) and therapeutic radionuclide (131I, 177Lu). Baseline data on endoradiotherapeutic use of 131I-MIP-1095, 177Lu-DKFZ-617 and 177Lu-PSMA-I and T in patients with metastatic prostate cancer demonstrate the prospects of molecular and morphological treatment. Thus, the aim of this work was to adapt the general concept of the indicator with the requirements of 99mTc. The availability and ease of preparation of 99mTc-PSMA indicators is fully compatible with the daily clinical workflow. In this regard, a lyophilized kit for the routine manufacture of 99mTc-PSMA-I and S appears to be available and reliable, which facilitates the distribution and production of new effective radiopharmaceuticals for clinical use in urology and, in particular, nuclear medicine. Key words: nuclear medicine, prostate cancer, single-photon emission computed tomography, prostate-specific membrane antigen.

Publisher

Institute of Nuclear Medicine and Diagnostic Radiology of the National Academy of Medical Sciences of Ukraine

Subject

General Earth and Planetary Sciences,General Environmental Science

Reference83 articles.

1. A dimerized urea-based inhibitor of the prostate-specific membrane antigen for 68Ga-PET imaging of prostate cancer / M. Schafer, U. Bauder-Wust, K. Leotta [et al.] // EJNMMI Res. – 2012. – Vol. 2. – P. 23. https://doi.org/10.1186/2191-219X-2-23.

2. A series of halogenated heterodimeric inhibitors of prostate specific membrane antigen (PSMA) as radiolabeled probes for targeting prostate cancer / K. P. Maresca, S. M. Hillier, F. J. Femia [et al.]// J Med Chem. – 2009. – Vol. 52. – P. 347-357. https://doi.org/10.1021/jm800994j.

3. A tabulated summary of the FDG PET literature / S. S. Gambhir, J. Czernin, J. Schwimmer [et al.] // J Nucl Med. – 2001. – Vol. 42. – P. 1-93.

4. Ackerstaff E. Choline phospholipid metabolism: a target in cancer cells? / E. Ackerstaff, K. Glunde, Z. M. Bhujwalla // J Cell Bioochem. – 2003. – Vol. 90 – P. 525-533. https://doi.org/10.1002/jcb.10659.

5. 2‐(3‐{1‐Carboxy‐5‐[(6‐[18F]fluoro‐pyridine‐3‐carbonyl)‐ amino]‐pentyl}‐ureido)‐pen tanedioic acid, [18F]DCFPyL, a PSMA‐based PET imaging agent for prostate cancer./ Y. Chen, M. Pullambhatla, C.A. Foss [et al.] // Clin Cancer Res. – 2011. – Vol.17. – P. 7645- 7653. https://doi.org/10.1158/1078-0432.CCR-11-1357.